TAKE Solutions Partners with MENE Research to Capture Emerging Pharma Markets Globally
TAKE Solutions Ltd.
has strengthened its Drug Safety and Pharmacovigilance solutions and services offering to cater to the growing needs of Pharma Emerging nations. The company has partnered with
MENE Research
wherein they together will cater to the Drug Safety requirements of Middle East, Europe, and West Asian countries.
Both the companies together will work towards providing the life science industry with strategy, solutions and services for drug safety operations thus ensuring global regulatory compliance and effective patient safety methodologies is followed. This partnership becomes strong by the fact that TAKE already has to its credit creating a framewokr—SafetyReady—along with a thought leadership in Drug Safety and Pharmacovigilance segments and Mene Research’s regional experience in Middle East, Europe, West Asia, etc.
TAKE Solutions extended Drug Safety and Pharmacovigilance Service Offerings with recent launch of SafetyReady for Oracle Argus Safety Suite Customers. Read
more
.
Putting Collective Insights Into Action to Advance Cancer Care: Key Examples From ASCO 2025
June 27th 2025At ASCO 2025, clinical operations leaders gained critical insights into how AI tools, bispecific antibodies, and evolving treatment paradigms are reshaping trial design, endpoint selection, and patient stratification.
Unifying Industry to Better Understand GCP Guidance
May 7th 2025In this episode of the Applied Clinical Trials Podcast, David Nickerson, head of clinical quality management at EMD Serono; and Arlene Lee, director of product management, data quality & risk management solutions at Medidata, discuss the newest ICH E6(R3) GCP guidelines as well as how TransCelerate and ACRO have partnered to help stakeholders better acclimate to these guidelines.
Funding Cuts Threaten Diversity in Clinical Research
June 27th 2025In this video interview, Kyle McAllister, co-founder, CEO, Trially, discusses how recent federal funding cuts are likely to undermine research focused on underrepresented populations, and why long-term investment in community-based studies is essential to closing persistent health equity gaps.
